Oncology and Hematology

161-176 of 246

• 

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  MinuteCE®

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  MinuteCE®

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  MinuteCE®

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  MinuteCE®

  Management of HR+, HER2- High-Risk EBC 

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  RestartResume

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  MinuteCE®

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  MinuteCE®

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  William J. Gradishar, MD; Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  RestartResume

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  MinuteCE®

  Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence   

  Alan Venook, MD

  1.25 program credits

  • 

    

    Alan Venook, MD

  1.25 program credits

• 

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  MinuteCE®

  Management of HER2-Low MBC Following First-Line Disease Progression

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  MinuteCE®

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  MinuteCE®

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  RestartResume

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  MinuteCE®

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  Sara Lonardi, MD; Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  • 

    

    Aparna R. Parikh, MD

  • 

    

    Alan Venook, MD

  1.25 program credits

• 

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  MinuteCE®

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers

  Sara Lonardi, MD; Aparna R. Parikh, MD

  1.25 credits 10 episodes

  • 

    

    Sara Lonardi, MD

  • 

    

    Aparna R. Parikh, MD

  • 

    

    Alan Venook, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  MinuteCE®

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  Susana Campos, MD, MPH; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 9
• 10
• 11
• 12
• 13
• …
• 15
• 16
• Next